Photo by Pixabay on Pexels.com
KUALA LUMPUR — MBSB Research has maintained a POSITIVE outlook on the healthcare sector following strong 4QFY25 earnings in the US and Europe, driven largely by pharmaceuticals. Demand for GLP-1 drugs, used in diabetes and obesity treatment, lifted pharmaceutical performance, while US hospitals reported resilient inpatient volumes despite labour shortages.
Medical devices and equipment also saw higher demand for high-margin treatments, with oncology drugs adding further momentum. Malaysian healthcare players are expected to mirror global trends, supported by medical tourism, government initiatives to reduce medical costs, recovery in the glove sector, and growth in the halal pharmaceutical market. These factors provide additional upside, positioning Malaysia’s healthcare industry for sustained expansion in 2026.
Read More News on Latest Malaysia
Read More News on Business News Malaysia
Read More News on SG Business News
Read More News on World Future TV
AMD says its EPYC processors deliver superior rack-scale throughput for agentic AI workloads, enabling enterprises…
CIMB and China CITIC Bank have signed an LOI to enhance China-ASEAN financial connectivity, supporting…
EG Industries is accelerating beyond traditional EMS, leveraging AI networking demand, 1.6T development, network switches…
Sime Darby Property has introduced a RM1.25 billion fund aimed at investing in new economy…
Pos Malaysia has consolidated all its courier offerings under the Pos Laju brand to streamline…
Jati launches Jati Chom Chom, a rice puff snack, expanding into the snack market with…
This website uses cookies.